ERLOTINIB

Background Information:

A selective inhibitor for the Epidermal Growth Factor Receptor (EGFR) tyrosine kinases.

Reference:

1. J.R. Johnson et al. Approval Summary for Erlotinib for Treatment
of Patients with Locally Advanced or Metastatic Non–Small Cell Lung
Cancer after Failure of at Least One Prior Chemotherapy Regimen. Clin.
Can. Res. 2005, 11, 6414-6421.
2. J. Porter et al. A dose escalation and pharmacokinetic (PK) trial of
weekly docetaxel combined with daily erlotinib in adult cancer patients.
J. Clin. Oncol. 2004, 22, 14S, 2119.

APIM050144: ERLOTINIB

CAS No.: 183321-74-6.
Molecular Formula: C₂₂H₂₃N₃O₄ · HCl.
Molecular Weight: 429.95.
Purity: >99.5% (HPLC at 214 and 254 nm).
QC: HPLC, ¹HNMR, and Quantitative Elemental Analysis.
Solubility: Soluble in DMSO and water.
Storage: Store at 0°C (short term), -20°C (long term), desiccated.